K. Sakthidasan¹, Bhekisipho Twala², S. Yuvaraj³, K. Vijayan^3,*, S. Praveenkumar³, Prashant Mani⁴, C. Bharatiraja³

CMC-Computers, Materials & Continua, Vol.67, No.3, pp. 3721-3735, 2021, DOI:10.32604/cmc.2021.014321 - 01 March 2021

Abstract The Internet of Things (IoT) is a heterogeneous information sharing and access platform that provides services in a pervasive manner. Task and computation offloading in the IoT helps to improve the response rate and the availability of resources. Task offloading in a service-centric IoT environment mitigates the complexity in response delivery and request processing. In this paper, the state-based task offloading method (STOM) is introduced with a view to maximize the service response rate and reduce the response time of the varying request densities. The proposed method is designed using the Markov decision-making model to… More >

Ping Wen^*, Sheng-Duo Chen^*, Jia-Rui Wang^†, Ying-He Zeng^*

Oncology Research, Vol.27, No.5, pp. 583-592, 2019, DOI:10.3727/096504018X15368325811545

Abstract This study evaluated the difference in treatment response and survival profiles between drug-eluting bead transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) treatments in Chinese hepatocellular carcinoma (HCC) patients. A total of 120 HCC patients were consecutively enrolled in this prospective cohort study, which showed that DEB-TACE achieved higher complete response (CR) (30.8%) compared with cTACE (7.4%) with no difference in overall response rate (ORR) for patients treated with DEB-TACE and cTACE (80.8% vs. 73.5%). In addition, DEB-TACE was associated with a lower rate of progressive disease (PD) compared with cTACE (1.9% vs. 11.8%). With… More >

Xiaoting Wei, Lili Mao, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Yan Kong, Jie Dai, Xuan Wang, Siming Li, Bixia Tang, Bin Lian, Xieqiao Yan, Xue Bai, Li Zhou, Jun Guo, Lu Si

Oncology Research, Vol.27, No.4, pp. 495-501, 2019, DOI:10.3727/096504018X15331163433914

Abstract Melanoma is an aggressive malignancy with a poor prognosis. Current studies show that imatinib treatment is a promising approach in treating advanced melanoma patients harboring c-Kit mutations or amplifications. We retrospectively analyzed the clinical medical records of 78 patients with metastatic melanoma harboring c-Kit mutations or amplifications. These patients were treated with imatinib at a dose of 400 mg/day continuously unless intolerable toxicities or disease progression occurred. Endpoints for exploration included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease of control rate (DCR). The median OS and PFS of all patients were More >